PMID- 9270551
OWN - NLM
STAT- MEDLINE
DCOM- 19970915
LR  - 20141120
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 37
IP  - 2 Pt 3
DP  - 1997 Aug
TI  - Tazarotene: the first receptor-selective topical retinoid for the treatment of 
      psoriasis.
PG  - S12-7
AB  - Tazarotene belongs to a novel, nonisomerizable class of retinoic acid receptor 
      (RAR)-specific retinoids, the acetylenic retinoids, and is the first topical 
      retinoid developed for the treatment of psoriasis. Tazarotene targets the 
      keratinocyte and modulates the major causes of psoriasis. Tazarotene is rapidly 
      metabolized by esterase to the active free acid tazarotenic acid, which is 
      rapidly eliminated in animal species. Tazarotene selectively transactivates RAR 
      beta and RAR gamma subtypes and is inactive at retinoid X receptors (RXRs). This 
      receptor selectivity could contribute to an optimized therapeutic index. 
      Tazarotene has low systemic absorption after topical administration. In 
      preclinical toxicity studies, high topical doses produced reversible topical 
      irritation, and lower doses were well tolerated. Topical doses were neither 
      teratogenic nor carcinogenic and were not sensitizing, phototoxic, or 
      photosensitizing. The topical delivery of tazarotene and limited systemic 
      exposure apparently result in a very low potential for systemic effects.
FAU - Chandraratna, R A
AU  - Chandraratna RA
AD  - Allergan, Inc., Irvine CA 92713, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Dermatologic Agents)
RN  - 0 (Nicotinic Acids)
RN  - 0 (Prodrugs)
RN  - 0 (Receptors, Retinoic Acid)
RN  - 0 (Retinoids)
RN  - 81BDR9Y8PS (tazarotene)
SB  - IM
CIN - J Am Acad Dermatol. 1999 Dec;41(6):1049-50. PMID: 10570404
MH  - Administration, Topical
MH  - Animals
MH  - Dermatologic Agents/pharmacology/*therapeutic use/toxicity
MH  - Humans
MH  - Nicotinic Acids/pharmacology/*therapeutic use/toxicity
MH  - Prodrugs/pharmacology/*therapeutic use/toxicity
MH  - Psoriasis/*drug therapy
MH  - Receptors, Retinoic Acid/*drug effects
MH  - Retinoids/pharmacology/*therapeutic use/toxicity
RF  - 34
EDAT- 1997/08/01 00:00
MHDA- 1997/08/01 00:01
CRDT- 1997/08/01 00:00
PHST- 1997/08/01 00:00 [pubmed]
PHST- 1997/08/01 00:01 [medline]
PHST- 1997/08/01 00:00 [entrez]
AID - S0190-9622(97)80395-7 [pii]
PST - ppublish
SO  - J Am Acad Dermatol. 1997 Aug;37(2 Pt 3):S12-7.